Clean Energy Fuels Corp. (NASDAQ:CLNE) recent rally took place on significantly more volume which surged nearly 926698 contracts on 11-Mar-19 versus its daily average of 562340. The first sale was made at $2.08 but later the stock became weaker, and closed with a gain of 7.77%. It was last traded at $2.22 apiece.Clean Energy Fuels Corp. (CLNE): Hold Candidate With 192.79% Upside Potential
Clean Energy Fuels Corp. is maintained at an average hold rating by 3 stock analysts, and there are at least 2.2% of shares outstanding that are currently legally short sold. The shares went up by 26.86% in value last month. Year-to-date it jumped 29.07%. Analysts are turning out to be more optimistic than before, with 2 of analysts who cover Clean Energy Fuels Corp. (NASDAQ:CLNE) advice adding it to buy candidate list. Wall Street experts also assign a $6.5 price target on Clean Energy Fuels Corp., pointing towards a 192.79% rally from current levels. The stock is trading for about -45.17% less than its 52-week high.
Revenue scored 9.69% growth from the previous quarter, coming up with $77.3 million.CLNE Adds 0.45% In A Week
This company shares (CLNE) so far managed to recover 66.92% since collapsing to its 52-week low. Over a week, it has seen its stock price volatility to stay at 5.69% while widening the period to a month, volatility was 5.35%. The share price has already crossed its 20 days moving average, floating at a distance of 6.63% and sits 12.72% higher versus its 50 days moving average. When looking at the past five sessions, the stock returned 0.45% gains and is down by -10% compared with its 200-day moving average of $2.2319. Also, Clean Energy Fuels Corp. (CLNE) needs to expand a 59.71% increase it experienced over the past twelve months.Trillium Therapeutics Inc. (NASDAQ:TRIL) Consensus Call At 1.5
As regular trading ended, Trillium Therapeutics Inc. (TRIL) stock brought in a -$0.06 drop to $0.67. The day started at a price of $0.72 but then traded as high as $0.7299 before giving part of the gains back. As for this week, analysts appear content to stick with their bright outlook with the consensus call at 1.5. Trillium Therapeutics Inc. is given 0 buy-equivalent recommendations, 0 sells and 1 holds. The company shares sank -92.06% from their peak of $8.4 and now has a $9.8 million market value of equity.Trillium Therapeutics Inc. Could Grow 1544.78% More
TRIL’s mean recommendation on Reuter’s scale presents no change from 2.33 thirty days ago to 2.33 now, which indicates a hold consensus from the analyst community. They see Trillium Therapeutics Inc. (TRIL) price hitting a mean target of $11.02 a share, meaning the stock still has potential that could lift the price another 1544.78% . Also, the recent close suggests the stock is underpriced by 3470.15% compared to the most bullish target.Trillium Therapeutics Inc. (TRIL) Returns -60.99% This Year
The company had seen its current volume reaching at 759570 shares in the last trade. That compares with the recent volume average of 1379640. At the close of regular trading, its last week’s stock price volatility was 8.9% which for the month reaches 11.72%. Trillium Therapeutics Inc. dipped to as low as $0.6608 throughout the day and has returned -60.99% in this year. At one point in the past year, the shares traded as low as $0.65 but has recovered 2.62% since then. [T4]